GRAIL/$GRAL
1D1W1MYTD1Y5YMAX
Capital at risk
About GRAIL
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
- Ticker
- $GRAL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 910
- Headquarters
- Menlo Park, United States
- Website
- grail.com
GRAIL Metrics
BasicAdvanced
$3.4B
-
-$9.75
3.25
-
Price and volume
Market cap
$3.4B
Beta
3.25
52-week high
$118.84
52-week low
$36.98
Average daily volume
793K
Financial strength
Current ratio
10.949
Quick ratio
10.55
Long term debt to equity
0.032
Total debt to equity
0.036
Profitability
EBITDA (TTM)
-378.383
Gross margin (TTM)
49.71%
Net profit margin (TTM)
-236.95%
Operating margin (TTM)
-323.04%
Effective tax rate (TTM)
26.04%
Revenue per employee (TTM)
$180,000
Management effectiveness
Return on assets (TTM)
-12.03%
Return on equity (TTM)
-16.12%
Valuation
Price to revenue (TTM)
18.256
Price to book
1.32
Price to tangible book (TTM)
4.41
Price to free cash flow (TTM)
-10.187
Free cash flow yield (TTM)
-9.82%
Free cash flow per share (TTM)
-7.373
Growth
Revenue change (TTM)
23.07%
Earnings per share change (TTM)
-25.39%
What the Analysts think about GRAIL
Analyst ratings (Buy, Hold, Sell) for GRAIL stock.
Analyst projections of the future price of GRAIL stock.
Bulls say / Bears say
Grail said on August 7, 2026 that the U.S. FDA plans to hold an advisory committee meeting on September 23, 2026 to review its Galleri multi-cancer screening test, boosting investor confidence and sending shares up 4%. (Reuters)
A March 10, 2026 WSJ article noted that a new law authorizing Medicare to reimburse multi-cancer early detection tests starting in 2028 if FDA-approved will unlock a significant addressable market for Galleri. (WSJ)
WSJ reports that Grail has sold over 475,000 Galleri tests since its 2021 launch, demonstrating strong commercial traction for its flagship product. (WSJ)
Grail shares plunged nearly 50% in premarket trading on February 20, 2026 after the company’s three-year cancer screening trial failed to meet its primary endpoint of a statistically significant reduction in combined Stage III and IV cancers, highlighting clinical execution risk. (Reuters)
The Galleri test did not achieve statistical significance in reducing late-stage cancers (Stages 3 and 4) in its NHS trial, raising doubts about its efficacy in critical patient populations. (WSJ)
Grail announced on March 12, 2026 that CEO Bob Ragusa will retire effective June 1, 2026, creating leadership transition risk at a pivotal moment following disappointing trial results. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2026.
GRAIL Financial Performance
Revenues and expenses
GRAIL Earnings Performance
Company profitability
Upcoming events
No upcoming events
GRAIL News
AllArticlesVideos
Funds containing GRAIL
AllUSDEURGBP
Fund name | Fund size | $GRAL weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.32% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.32% |
iShares Healthcare Innovation£DRDR | £1B | 0.32% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.22% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.22% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.